More than 4 million hernia repair surgeries are performed in the United States every year, making it one of the most common elective procedures in American medicine. In the vast majority of these operations, surgeons implant a synthetic mesh device to reinforce the abdominal wall and prevent recurrence. For most patients the mesh performs as intended. For tens of thousands, however, the device has shrunk, migrated, degraded, or sparked a chronic inflammatory response — producing complications that are often more debilitating than the original hernia. Those patients have increasingly turned to the courts, creating one of the largest ongoing mass-tort litigations in US history.
This guide breaks down the current settlement landscape: which manufacturers are defendants, what patients with different injury profiles are actually receiving, and what factors determine where any individual case lands in the compensation range. It also explains the Bard $184 million bellwether verdict that reshaped the litigation, the MDL status of each major defendant group, and how the statute of limitations works for patients who may have had surgery years ago.
Scale of the Litigation: Thousands of Cases, Multiple MDLs
Hernia mesh litigation is not a single case or a single defendant. It comprises several parallel mass-tort proceedings, each targeting a different manufacturer and product line. As of mid-2025 the active federal multidistrict litigation dockets include:
- In re: Davol/C.R. Bard Hernia Mesh Products Liability Litigation (S.D. Ohio, MDL 2846) — the largest hernia mesh MDL in history, with over 20,000 cases at peak enrollment
- In re: Ethicon Physiomesh Flexible Composite Mesh Products Liability Litigation (N.D. Georgia, MDL 2782) — focused on Ethicon's recalled laparoscopic mesh product
- In re: Atrium Medical C-QUR Mesh Products Liability Litigation (D. New Hampshire, MDL 2753)
- In re: Covidien Hernia Mesh Products Liability Litigation (D. Massachusetts, MDL 2988) — covering the Parietex and other product lines
Beyond the federal MDLs, substantial state-court litigation continues in New Jersey (a traditional venue for pharmaceutical and medical device cases), California, and New York. The aggregate number of filed hernia mesh cases across all venues has exceeded 30,000 claims in recent years, though active pending totals fluctuate as cases resolve and new ones are filed.
The Major Defendants and Their Products
Understanding who makes what product matters because settlement values vary considerably between manufacturers, reflecting differences in the nature and severity of documented defects, the extent of internal corporate knowledge, and how aggressively each defendant has litigated.
C.R. Bard / Davol (now BD)
Bard (now a division of Becton Dickinson) manufactured several polypropylene mesh products that became central to the litigation, most notably the Composix Kugel Mesh and the PerFix Plug. The Composix Kugel was designed with a memory recoil ring intended to help the device self-expand inside the abdominal cavity. In practice, the ring has fractured in numerous patients, with broken fragments migrating through tissue and in some cases perforating the bowel — a life-threatening complication. The FDA issued a Class I recall of certain Composix Kugel sizes as early as 2005 and expanded it in 2006, affecting hundreds of thousands of units. Internal Bard documents obtained in discovery showed company engineers were aware of the ring fracture problem before the recall.
Bard is also the defendant in the most consequential bellwether verdict of the entire hernia mesh litigation: a $184 million jury verdict in November 2019 in the Southern District of Ohio. The jury awarded $80 million in compensatory damages and $104 million in punitive damages to a plaintiff who required multiple surgeries to address complications from a Bard Davol 3D Max mesh. The punitive award reflected the jury's finding that Bard had acted with conscious disregard of patient safety. That verdict was subsequently settled confidentially while Bard appealed, as is typical in post-verdict MDL practice, but the $184 million number sent a clear signal to all hernia mesh defendants about their exposure.
Ethicon (Johnson & Johnson)
Ethicon's hernia mesh litigation centers on the Physiomesh Flexible Composite Mesh, which the company voluntarily withdrew from the market in May 2016 following registry data from European databases showing significantly elevated recurrence and reoperation rates compared to competing products. The withdrawal was notable because Ethicon itself initiated it — there was no FDA-compelled recall — after analysis of Danish Hernia Database and Swedish Hernia Register data showed Physiomesh patients had far higher rates of reoperation within 36 months of implant.
The MDL in the Northern District of Georgia has processed thousands of claims. Ethicon has taken a relatively aggressive settlement posture in cases involving documented reoperation, which the registry data makes easy to identify. The J&J parent company's significant financial resources mean defendants in the Ethicon MDL are negotiating with a counterparty capable of reaching large aggregate resolutions, though no global settlement has been announced as of mid-2025.
Atrium Medical (C-QUR)
Atrium Medical's C-QUR mesh incorporates an omega-3 fatty acid coating intended to reduce the inflammatory response during implantation. Plaintiffs allege that the coating degrades unpredictably, triggering an adhesion formation process that causes the mesh to fuse with surrounding tissue, including the bowel. Adhesion formation is particularly dangerous because it can cause bowel obstruction years after implant, and surgery to free bowel adhesions is complex and risky. The Atrium MDL in New Hampshire has moved more slowly than the Bard and Ethicon MDLs, but cases involving documented adhesion-related complications have settled at values consistent with other manufacturers.
Covidien / Medtronic (Parietex)
Covidien, subsequently acquired by Medtronic, makes the Parietex product line, a composite mesh using polyester rather than polypropylene. Polyester mesh carries its own degradation concerns: the material can hydrolyze over time in the body's aqueous environment, weakening the mesh structure and causing fragmentation. The Covidien MDL in Massachusetts is one of the more recent additions to the hernia mesh litigation landscape, having been consolidated in 2021, and its bellwether trial process is ongoing.
Settlement Amounts by Complication Type
Settlement value in hernia mesh cases is driven primarily by the nature and severity of the complication, the number of revision surgeries required, and the quality of the documentary evidence linking the complication to the specific device. The following ranges reflect settlements observed across the major MDLs and state-court litigations through mid-2025.
| Complication Type | Typical Settlement Range | Notes |
|---|---|---|
| Chronic pain, no revision surgery | $65,000 – $150,000 | Harder to prove causation; lower damages |
| Mesh infection requiring removal | $100,000 – $250,000 | Strong medical records; documented surgical costs |
| Single revision surgery (migration or adhesion) | $100,000 – $220,000 | Well-documented; baseline range for most settled cases |
| Two revision surgeries | $200,000 – $350,000 | Recurring harm strengthens both liability and damages |
| Three or more revisions / permanent disability | $400,000 – $1,000,000+ | High trial value; defendants prioritize settlement |
| Bowel perforation / bowel resection | $300,000 – $750,000+ | Life-threatening complication; high punitive potential |
| Composix Kugel ring fracture cases | $200,000 – $500,000+ | Pre-recall Bard knowledge is well-documented |
| Ethicon Physiomesh reoperation cases | $150,000 – $400,000 | Registry data makes causation evidence strong |
The Bard $184 Million Bellwether Verdict: What It Means
Bellwether trials are a structured feature of MDL litigation. When thousands of cases involving similar claims are centralized before a single judge, it is impractical to try them all. Instead, the MDL judge selects a representative sample of cases — the bellwethers — to try before a jury. The verdicts serve as data points: they tell both sides what a jury is likely to do with a typical case, which informs settlement negotiations across the remaining docket.
In November 2019, the first Bard bellwether trial resulted in a verdict of $184 million for a plaintiff who had experienced multiple complications after implantation of a Bard Davol 3D Max Mesh. The award broke down as $80 million in compensatory damages and $104 million in punitive damages. The punitive component was significant: it reflected the jury's conclusion not merely that Bard's product was defective, but that Bard had acted with conscious disregard for patient safety. Internal corporate documents presented at trial showed Bard's awareness of complication trends before they were disclosed to surgeons or the FDA.
Bard appealed the verdict, but the case settled confidentially while the appeal was pending — as is the standard playbook after a large MDL bellwether verdict. The settlement amount was not publicly disclosed, which is also standard, but the $184 million jury number exerted enormous pressure on the entire MDL. Defendants who previously offered low-value settlements revised their positions substantially. Plaintiffs' attorneys used the verdict in negotiations for the thousands of remaining cases. It established, conclusively, that an Ohio jury was willing to punish Bard not just for selling a defective product but for the corporate conduct surrounding it.
Subsequent bellwether trials in the Bard MDL have produced additional verdicts, some lower and some higher, as the trial pool has included cases with varying complication profiles. This variance is normal and expected: bellwether trials are deliberately selected to span the range of case quality, so results naturally vary. What the aggregate bellwether data confirms is that well-documented multi-revision cases in federal court carry jury risk in the hundreds of millions of dollars for Bard, which is why the company has been settling cases at a significant pace.
Product Defect Allegations: What the Lawsuits Actually Claim
Hernia mesh cases are product liability cases, which means plaintiffs must prove that the mesh was defective and that the defect caused their injury. The specific defect theories vary somewhat by product but cluster around four documented failure modes.
Polypropylene degradation: Most hernia mesh products are made from polypropylene, a polymer that manufacturers have historically described as biologically inert. Research published since the mid-2000s, however, has demonstrated that polypropylene oxidizes in the body over time, becoming brittle and potentially generating degradation byproducts that trigger an inflammatory response. Plaintiffs argue that manufacturers knew about polypropylene degradation research and either suppressed it or failed to investigate it adequately before marketing their products as safe for permanent implantation.
Mesh shrinkage (contraction): Multiple studies have documented that polypropylene mesh shrinks after implantation by anywhere from 20% to 50% of its original surface area as the body's fibrotic response tightens around it. Shrinkage causes the mesh to pull on surrounding tissue, creating chronic pain, restricting movement, and in some cases causing the hernia to recur as the mesh no longer covers the original defect. Manufacturers knew about contraction rates from their own clinical data; the allegation is that they did not adequately warn surgeons or patients.
Mesh migration: Some devices, particularly plug-type products like the Bard PerFix Plug, have been documented to migrate from the original implantation site into adjacent tissue. Migration can bring the mesh into contact with the bladder, vas deferens (in male patients), or bowel. Bowel contact is particularly dangerous because the polypropylene can erode through the bowel wall, causing fistula formation or perforation — both potentially fatal complications requiring emergency surgery.
Coating degradation (C-QUR specific): Atrium's C-QUR mesh relies on its omega-3 fatty acid coating to provide a bioresorbable barrier between the mesh and internal organs. The allegation is that the coating degrades too rapidly or unpredictably, exposing the underlying polypropylene to direct organ contact before adequate tissue incorporation has occurred, and triggering the adhesion process before the mesh has had time to be properly anchored by the body's own tissue growth.
Statute of Limitations and the Discovery Rule
One of the most common questions from patients with hernia mesh injuries is whether it is too late to file. The short answer, for many patients, is that the clock may not have started when they think it did.
Most states apply a statute of limitations of 2 to 4 years to product liability claims. In a typical injury case — a car accident, for example — the clock starts running on the date of the injury. Applied literally to hernia mesh cases, this would mean the clock starts on the date of the original surgery. Under that interpretation, a patient who had surgery in 2015 would have had until 2017 or 2019 to file, and would now be time-barred.
But hernia mesh cases do not work that way in most jurisdictions, because of the discovery rule. The discovery rule provides that the statute of limitations does not begin to run until the plaintiff knew or, in the exercise of reasonable diligence, should have known that their injury was caused by the defendant's product. In the hernia mesh context, this means:
- A patient who had surgery in 2014 and experienced immediate complications that were documented as mesh-related has known since 2014 or shortly after, and the clock has run from that point.
- A patient who had surgery in 2014 but only developed chronic pain diagnosed as mesh-related in 2021, or who only learned that their hernia recurrence was caused by mesh shrinkage after seeing a specialist in 2022, may have a discovery date of 2021 or 2022 — meaning the statute of limitations may not have expired yet.
- Patients whose Composix Kugel ring fracture was only identified on imaging performed years after the original surgery have argued, often successfully, that their discovery date is the date of that imaging.
The discovery rule analysis is highly fact-specific and varies by state. Patients who suspect their complications may be mesh-related should consult a hernia mesh attorney promptly rather than assuming their claim is time-barred. Several states also have discovery-rule exceptions or tolling provisions for medical device cases that can extend filing deadlines further.
How Revision Surgery Count Drives Case Value
If there is a single factor that correlates most strongly with settlement value in hernia mesh cases, it is the number of revision surgeries the patient has undergone. Each additional surgery adds to case value in three distinct ways.
First, revision surgeries add direct economic damages. Hernia revision surgery at a hospital facility costs between $15,000 and $60,000 per procedure depending on complexity, surgeon fees, anaesthesia, and whether the surgery requires an overnight stay. Patients who have had three revision surgeries have documented medical costs of $45,000 to $180,000 from those procedures alone, before including the original surgery, emergency room visits, imaging, specialist consultations, and medications.
Second, revision surgeries create compounding non-economic damages. Each surgery involves recovery time, physical pain, psychological distress, and disruption of work and family life. Juries are asked to compensate not just the aggregate but the repeated nature of the experience — each recovery period, each return to the operating room, each setback when the patient hoped the last surgery had fixed the problem. Multiple revisions are narratively powerful in ways that a single isolated complication is not.
Third, and perhaps most importantly for negotiation purposes, patients with multiple revision surgeries have stronger evidence that the mesh itself was the problem. Defendants' standard defence in hernia mesh cases is that the complication was caused by surgical technique, patient anatomy, or underlying medical conditions rather than the product. A patient who had the same complication return after two different surgeons performed two separate revisions makes that argument significantly harder to sustain.
Free Tool
Estimate Your Hernia Mesh Settlement Value
Enter your mesh product, complication type, number of revision surgeries, and state. Get a personalised 2025 settlement range estimate.
Use the Calculator →Who Qualifies to File and How to Get Started in 2025
Patients who may have a viable hernia mesh claim are those who:
- Had a hernia repair surgery using synthetic mesh from one of the major defendant manufacturers (Bard/Davol, Ethicon, Atrium, Covidien, or others)
- Experienced complications that a physician documented as potentially or definitively related to the mesh — including infection, chronic pain, recurrence, adhesions, migration, or the need for revision surgery
- Have not yet resolved the case through a prior settlement or litigation
- Filed or can still file within the applicable statute of limitations (accounting for the discovery rule)
The first practical step is identifying the manufacturer and product name of the mesh that was implanted. This information appears in surgical operative notes and implant stickers — small adhesive labels placed in the patient's medical record at the time of surgery identifying the specific device by model and lot number. Patients who do not have their surgical records should request them from the hospital or surgical center where the procedure was performed. Hospitals are required to retain implant records for a minimum of 10 years, and many retain them longer.
Once the product is identified, a hernia mesh attorney can determine whether it falls within an active MDL or state mass-tort proceeding. Most hernia mesh attorneys work on a contingency fee basis — they receive no fee unless the case produces a recovery — and offer free initial consultations. Given the statute of limitations concerns, patients who believe they may have a claim should not delay. The difference between filing six months before a deadline and filing after it is the difference between a potentially significant recovery and no recovery at all.
Frequently Asked Questions
- What is the average hernia mesh lawsuit settlement amount in 2025?
- Hernia mesh settlements in 2025 range from approximately $65,000 for single-complication cases to over $500,000 for patients who required multiple revision surgeries with serious complications such as bowel perforation or permanent disability. The median settlement across all complication types falls between $150,000 and $250,000 for well-documented cases. Jury verdicts, when cases go to trial, have produced awards from $1 million to $184 million (the Bard bellwether verdict), though most defendants settle before trial to avoid that exposure.
- Which hernia mesh brands have paid the largest settlements?
- Bard (C.R. Bard / Davol, now BD) has paid the most in aggregate, with over 20,000 MDL cases and a bellwether jury verdict of $184 million in 2019. Ethicon voluntarily recalled Physiomesh in 2016 and has settled thousands of cases in its MDL. Atrium Medical (C-QUR) and Covidien (Parietex) have also resolved significant numbers of claims. No manufacturer has announced a global class-action settlement; cases are individually valued and resolved on a rolling basis within each MDL.
- What is the statute of limitations for hernia mesh lawsuits?
- The limitation period varies by state, typically 2 to 4 years, but the discovery rule applies in most jurisdictions. The clock does not start from the date of the original surgery but from the date the patient knew or reasonably should have known their injury was caused by a defective mesh. Patients who had surgery years ago but only recently connected their complications to the mesh may still have viable claims. An attorney can evaluate the specific discovery date for your situation.
- How does the number of revision surgeries affect hernia mesh settlement value?
- The number of revision surgeries is one of the most important settlement-value drivers. A single revision surgery typically puts cases in the $100,000–$220,000 range. Two revisions push values to $200,000–$350,000. Three or more revisions, especially involving bowel resection or permanent functional loss, regularly produce settlements of $400,000 to over $1 million. Each additional surgery adds documented medical costs, compounds pain and suffering damages, and makes the defence argument that complications were not mesh-related progressively harder to sustain.